[
{
	"page":"ENAS5304_1.0.0.0",
	"text":"Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth De Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic.   ESMO CLINICAL PRACTICE GUIDELINES Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi64–72 http://‍annonc.oxfordjournals.org/‍content/‍‍24/‍suppl_6/‍vi64.full.pdf+html Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv22–40 https://academic.oup.com/annonc/article-pdf/28/suppl_4/iv22/3958158/mdx224.pdf Familial risk - colorectal cancer: ESMO Clinical Practice Guidelines Balmaña J, Balaguer F, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi73–80 http://annonc.oxfordjournals.org/content/‍24/‍suppl_6/vi73.full.pdf+html Anal cancer: ESMO-‍ESSO-‍ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Glynne-‍Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A and Arnold D Ann Oncol 2014; 25(Suppl 3):iii10-20. http://annonc.oxfordjournals.org/content/‍25/‍suppl_3/iii10.full.pdf+html   Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Van Cutsem E, Cervantes A, Nordlinger B and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2014; 25 (Suppl 3):iii1-9 http://annonc.oxfordjournals.org/content/‍25/‍suppl_3/iii1.full.pdf+html ESMO CONSENSUS STATEMENTS ESMO Consensus Guidelines for Management of Patients with Metastatic Colorectal Cancer Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-‍Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-‍Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJG, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A and Arnold D Ann Oncol 2016; 27: 1386-422. http://‍annonc.oxfordjournals.org/‍content/‍‍27/8/1386.full.pdf+html ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPG) and consensus statements on the management of lower gastrointestinal (GI) tumours (early colon cancer, rectal cancer, familial colorectal cancer [CRC] risk, metastatic CRC and anal cancer). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-‍up. The ESMO CPG and consensus statements on lower GI tumours are intended to provide you with a set of recommendations for the best standards of care for lower GI tumours, using evidence-‍based medicine. Implementation of ESMO CPG and consensus statements facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on evidence-‍based management of lower GI tumours. Please visit http://www.esmo.org or http:/‍/‍oncologypro.esmo.org to view the full guidelines and consensus statements."
},
{
	"page":"ENAS5304_2.0.0.0",
	"text":"2.0.0.0 DIAGNOSIS Clinical or biochemical suspicion of metastatic colorectal cancer (mCRC) should always be confirmed by radiological imaging and histological confirmation The first choice is an abdominal/‍pelvic and thoracic computed tomography (CT) scan followed, in cases of doubt or if further information is required by a second method, such as ultrasound (US, including contrast-‍enhanced ultrasound [CEUS]), magnetic resonance imaging (MRI) or positron emission tomography (PET)-CT scan, depending on the localisation of the metastases US: may be helpful to characterise liver lesions MRI: helpful to detect liver, peritoneal or pelvic metastases PET-‍CT: to detect extrahepatic disease A stepwise imaging approach is recommended in relation to therapeutic possibilities, rather than the use of all imaging modalities in all patients"
},
{
	"page":"ENAS5304_2018032280",
	"text":"3.0.0.0 MOLECULAR PATHOLOGY AND BIOMARKERS Ideally, 10 diagnostic tumour/‍biopsy/‍endoscopy samples should be collected Additional frozen material should be collected, to facilitate any future ‘new’ tests    "
},
{
	"page":"ENAS5304_2018032281",
	"text":"The time between tissue sampling and fixation should be minimised (to a few minutes) to prevent degradation of proteins and nucleic acids Fixation in 10% neutral buffered formalin (4% formaldehyde solution) is recommended and is generally compatible with protein, RNA and/‍or DNA biomarker analyses Fixation time should be 6–48 hours Longer or shorter times may adversely affect testing Acidic fixatives (e.g. Bouin) and accelerated fixation with heated formalin are not recommended as they degrade nucleic acids and tissue morphology, respectively Biomarker analysis should ideally be carried out immediately after the sections have been cut and within 4–6 weeks to avoid degradation of epitopes and DNA"
},
{
	"page":"ENAS5304_2018032282",
	"text":"The primary pathologist should review all tumour specimens and select the block for testing, using haematoxylin and eosin staining to ensure sufficient neoplastic cell content This is particularly important for DNA/RNA-based biomarker testing, as too few neoplastic cells can result in dilution of mutant alleles and false negative results A neoplastic cell content of at least 50% is recommended when using low- sensitivity techniques, such as Sanger sequencing Where tumour cell content is low, manual macro-dissection of pathologist-identified areas of tissue from the slide can be used to enrich the content"
},
{
	"page":"ENAS5304_2018042683",
	"text":"Archival primary tumour tissue can be used for testing, as well as biopsies of the primary or metastatic lesions For RAS mutation testing, tissue from a primary tumour or liver metastasis is recommended as studies show discordance rates for KRAS exon 2 mutation testing between primary tumours and metastases of approximately 5% for liver metastases and 25% for lymph node metastases. These data can be extrapolated to expanded RAS analysis Tissue from other metastatic sites, such as lymph node or lung, should be used only when primary tumour or liver metastases samples are not available Cell-free DNA (cfDNA) should not be used for routine work-up (see comments below)"
},
{
	"page":"ENAS5304_4.2.1.0",
	"text":"4.2.0.0 RAS/‍RAF and MSI 4.2.1.0 RAS RAS mutation status is a negative predictive biomarker for therapeutic choices involving anti-‍epidermal growth factor receptor (EGFR) monoclonal antibody therapies for metastatic disease Expanded RAS analysis is mandatory prior to treatment and should be conducted on all patients eligible/‍being considered for treatment with anti-‍EGFR antibodies (cetuximab and panitumumab) This should include at least KRAS exons 2, 3 and 4 (codons 12, 13, 59, 61, 117 and 146) and NRAS exons 2, 3 and 4 (codons 12, 13, 59, 61 and 117) The exact cut-‍off for clinically relevant RAS mutant allele frequencies has not been determined Turnaround time for (expanded) RAS testing should be ≤ 7 working days from the time of receipt of the specimen by the testing laboratory to the time of issuing of the final report for most specimens Systems to ensure rapid and reliable transit of tissues should be established Validation, and/‍or verification, of RAS testing assays is required and laboratories should be appropriately accredited"
},
{
	"page":"ENAS5304_4.2.2.0",
	"text":"4.2.2.0 BRAF BRAF mutations (generally V600E) are found in 8–12% of patients and are a significant negative prognostic marker BRAF mutations are a negative predictor for EGFR antibody therapy in later lines although their role in earlier lines has not been fully ascertained BRAF mutation status should be assessed alongside the assessment of RAS mutation status, ideally at diagnosis, for prognostic assessment and/‍or potential determination of treatment intensity and for selection for clinical trials"
},
{
	"page":"ENAS5304_4.2.3.0",
	"text":"4.2.3.0 Microsatellite instability Microsatellite instability (MSI) is found in 4–8% of tumours and confers an inferior prognosis, which may be driven by the frequent presence of BRAF mutations MSI testing can assist in the setting of genetic counselling Most studies in mCRC show that MSI status is not relevant as a single predictive marker for response to chemotherapy but is strongly predictive for the clinical benefit of immune checkpoint inhibitors"
},
{
	"page":"ENAS5304_4.2.4.0",
	"text":"4.2.4.0 ChT sensitivity/‍ toxicity biomarkers Dihydropyrimidine dehydrogenase (DPD) testing before 5-‍fluorouracil (5-FU) administration is not generally recommended but remains an option and can be used prior to reintroduction of 5-FU in patients previously experiencing severe 5-FU toxicity Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) phenotyping remains an option and should be performed in patients with a suspicion of UGT1A1 deficiency, as reflected by low conjugated bilirubin, and in patients where an irinotecan dose of > 180 mg/m2 per administration is planned Excision repair cross-‍complementation group 1 (ERCC1) expression is not recommended as a biomarker for treatment decisions involving oxaliplatin in routine clinical practice Thymidylate synthase (TS) activity and TS enhancer region (TSER) genotyping are not recommended for use in clinical practice"
},
{
	"page":"ENAS5304_4.2.5.0",
	"text":"4.2.5.0 Emerging biomarkers A number of emerging biomarkers are not currently recommended for routine patient management outside the clinical trial setting, including: PIK3CA exon 20 mutations; phosphatase and tensin homologue (PTEN) loss; EGFR protein expression, EGFR ligands (amphiregulin, epiregulin and transforming growth factor apha [TGF-α]) and EGFR amplification, copy number and ectodomain mutations; human epidermal growth factor receptor 2 (HER2) amplification or activating mutations; HER3 and MET receptor overexpression"
},
{
	"page":"ENAS5304_4.2.6.0",
	"text":"4.2.6.0 Emerging technologies Although circulating tumour cell (CTC) number correlates with prognosis in patients with mCRC, the clinical utility of CTC assessments is not yet clear and cannot be recommended The utility of liquid circulating tumour (ct)DNA biopsies to guide treatment decisions is under investigation in clinical trials and cannot yet be recommended in routine practice Whole genome, whole exome and whole transcriptome analyses should be performed only in a research setting An international consortium-‍developed molecular classification system which defined four different sub-‍types – MSI immune, canonical, metabolic and mesenchymal – may form the basis for future clinical trials"
},
{
	"page":"ENAS5304_5.1.0.0",
	"text":"5.10.0.0 Mets. at unfavourable sites 5.1.0.0 Overview The optimal treatment of mCRC should involve an expert multidisciplinary team (MDT), including a colorectal surgeon, a specialist hepatobiliary and/‍or lung surgeon, a pathologist, a diagnostic radiologist and radiation oncologist and medical oncologists as standard"
},
{
	"page":"ENAS5304_5.2.1.0",
	"text":"5.2.0.0 Mgmt. of patients with OMD, LAT, surgery 5.2.1.0 Oligometastatic disease OMD is characterised by metastases at up to three different sites, with five or more lesions, predominantly visceral and occasionally lymphonodal Typically, involved sites are the primary tumour and other involved sites, such as the liver, lung peritoneum, nodes and ovary Treatment strategy should be based on the possibility of achieving complete ablation of all tumour masses using surgical R0 resection and/‍or interventional LAT For OMD confined to a single organ (commonly liver), or a few organs, surgery is the standard treatment and is the only option to be proven potentially curative For more extensive OMD, involving more sites or lesions, systemic treatment is the standard of care and should be considered as the initial part of every treatment strategy The best local treatment should be selected from a toolbox of procedures, as shown in the figure see here, according to disease localisation, treatment goal, treatment-related morbidity and patient-related factors, such as comorbidities and age Liver-‍directed therapy is the best-‍established approach, but options include stereotactic ablative body radiotherapy (SBRT) and radiofrequency ablation (RFA), peritonectomy with/‍without hyperthermic intraperitoneal chemotherapy (HIPEC) and nodal dissection Patients with lung metastases have better outcomes, and a ‘watch and wait’ strategy (or sequential approach) may be appropriate"
},
{
	"page":"ENAS5304_5.2.2.0",
	"text":"5.2.2.0 Liver metastases and surgical resection The treatment strategy for colorectal liver metastases (CLM) should be directed towards complete resection, whenever possible. Decisions should be based on oncological and technical criteria, as shown in this figure here and the table here CLM are technically resectable as long as complete macroscopic resection is feasible while maintaining at least a 30% future liver remnant or a remnant liver to body weight ratio > 0.5 Oncological criteria include the number of lesions and the presence (or suspicion) of extrahepatic disease and all criteria used in the FONG score"
},
{
	"page":"ENAS5304_5.4.0.0",
	"text":"CATEGORISATION OF PATIENTS ACCORDING TO ONCOLOGICAL AND TECHNICAL CRITERIA FOLFOX, leucovorin/infusional 5-fluorouracil/oxaliplatin"
},
{
	"page":"ENAS5304_5.5.0.0",
	"text":"5.5.0.0 Contraindications to hepatic resection CONTRAINDICATIONS TO HEPATIC RESECTION IN PATIENTS WITH COLORECTAL LIVER METASTASES CATEGORY CONTRAINDICATION Technical (A)   1. Absolute Impossibility of R0 resection with ≥ 30% liver remnant Presence of unresectable extrahepatic disease 2. Relative R0 resection possible only with complex procedure (portal vein embolisation, two-‍stage hepatectomy, hepatectomy combined with ablation*) R1 resection Oncological (B)   1. Concomitant extrahepatic disease (unresectable) 2. Number of lesions ≥ 5 3. Tumour progression Patients should be categorised as A1 or A2/B1, B2, or B3 *Includes all methods, including RFA Adapted from: Adam R, et al. Oncologist 2012;17:1225–39, with permission from AlphaMed Press. RO, resection with negative margins; R1, resection with microscopic residual disease; RFA, radiofrequency ablation"
},
{
	"page":"ENAS5304_5.6.0.0",
	"text":"Imaging in the identification of resectable/unresectable disease 5.6.0.0 Imaging identification Imaging should comprise firstly an abdominal/‍pelvic and thoracic CT scan and, in the case of doubt, a second method – such as US (CEUS), MRI or PET/‍CT scan depending on the localisation of the metastases A stepwise imaging approach is the recommended policy, in relation to the therapeutic possibilities, rather than the use of all imaging modalities in all patients For metachronous metastases, histopathological or cytological confirmation of metastases should be obtained if the clinical or radiological presentation is either atypical or very late (e.g. later than 3 years) after the initial diagnosis of the primary tumour Resectable metastases do not need histological or cytological confirmation before resection"
},
{
	"page":"ENAS5304_5.7.0.0",
	"text":"Liver metastases that are technically resectable up front 5.7.0.0 Resectable liver metastases The primary goal is cure Both technical criteria for resection and prognostic considerations define the need for systemic perioperative therapy In patients with clearly resectable disease and favourable prognostic criteria, perioperative treatment may not be necessary and upfront R0 resection is justified In technically resectable disease where the prognosis is unclear or probably unfavourable, perioperative combination chemotherapy (3 months prior to and post-‍surgery) with leucovorin/infusional 5-FU/oxaliplatin (FOLFOX) or capecitabine/oxaliplatin (CAPOX) should be administered Targeted agents should not be used in this setting Where the criteria for prognosis and resectability are not sharply defined, including patients with synchronous onset of metastases, perioperative therapy should be considered (as part of a continuum of treatment option) Adjuvant chemotherapy is not recommended for patients with favourable oncological and technical (surgical) criteria who have not received perioperative chemotherapy, but may be beneficial for patients with unfavourable criteria In patients who have not received any previous chemotherapy, adjuvant treatment with FOLFOX or CAPOX is recommended (unless patients were previously recently exposed to oxaliplatin-‍based adjuvant chemotherapy) Decision-‍making should include the patient’s characteristics and preferences"
},
{
	"page":"ENAS5304_5.8.0.0",
	"text":"Unresectable colorectal liver metastases with ‘conversion’ as a strategic treatment goal 5.8.0.0 Unresectable colorectal liver mets. Any patient with limited liver and/‍or lung metastases should be considered a candidate for potential secondary resection Conversion therapy offers the best means of converting unresectable disease to resectable Response to systemic treatment is a strong prognostic indicator with conversion therapy Resectability should be assessed after 2 and then 4 months of optimal treatment Up to 75% of patients will relapse (mainly in the liver) and ablative techniques, such as RFA or SBRT, may be used as an adjunct to surgery to achieve no evidence of disease (NED) There is currently no standard for the treatment of synchronous CLM but the recommendation is for more aggressive treatment and preoperative chemotherapy"
},
{
	"page":"ENAS5304_5.9.0.0",
	"text":"5.9.0.0 Conversion treatment Resection rates are correlated with response to systemic therapy and regimens leading to high response rates (RRs) and/‍or fast onset of response and/‍or large tumour reduction (Early Tumour Shrinkage, Depth of Response) are recommended for potentially resectable disease with conversion as the goal There is uncertainty surrounding the best combination In RAS wild-‍type disease, a cytotoxic doublet + an anti-‍EGFR antibody seems to have the best benefit:risk ratio, although the combination of leucovorin/infusional 5-FU/oxaliplatin/irinotecan (FOLFOXIRI) + bevacizumab may also be considered and, to a lesser extent, a cytotoxic doublet + bevacizumab In RAS mutant disease, a cytotoxic doublet + bevacizumab or FOLFOXIRI + bevacizumab Patients must be re-‍evaluated regularly to prevent the overtreatment of resectable patients as the maximal response is expected to be achieved after 12–16 weeks of therapy in most patients Total therapy duration should not exceed 6 months"
},
{
	"page":"ENAS5304_5.10.0.0",
	"text":"5.10.0.0 Mets. at unfavourable sites Metastases at unfavourable/uncommon sites and role of ablative treatment with or without surgery Patients with a limited number of lesions and involved sites should be regarded as having OMD and should be treated according to the standard treatment algorithm, as shown in the figure here In this situation, ablation of visible sites is unlikely to lead to cure, but may allow discontinuation of systemic therapy with the possibility of a relapse-/disease-‍free interval RFA, microwave ablation, cryoablation, SBRT and, to a lesser extent, embolisation techniques are all feasible Selection of ablative treatments from the toolbox differ according to the size and localisation of metastases, the rates of control achieved, the invasiveness of the technique, prognostic considerations, patient factors and preferences and life expectancy, as well as to the local expertise of the treating team This strategic treatment approach should be evaluated and pursued further in suitable patients"
},
{
	"page":"ENAS5304_5.11.0.0",
	"text":"5.11.0.0 Standard treatment algorithm for OMD STANDARD TREATMENT ALGORITHM FOR PATIENTS WITH OLIGOMETASTATIC DISEASE RFA, radiofrequency ablation; SBRT, stereotactic body radiotherapy; SIRT, selective internal radiotherapy"
},
{
	"page":"ENAS5304_5.12.0.0",
	"text":"5.12.0.0. Toolbox of LATs Current techniques within the LAT toolbox comprise local thermal ablation (RFA, cryoablation, microwave ablation), conformal radiation techniques and embolisation techniques (chemoembolisation or radioembolisation with yttrium-‍labelled microspheres) In patients with unresectable liver metastases only, or OMD, suitable LAT (such as local thermal ablation or high conformal radiation techniques [e.g. SBRT, high dose-‍rate (HDR)-brachytherapy]) can be considered The decision should be taken by a MDT, based on tumour and disease characteristics, local experience of the treating MDT and patient preference In patients with lung-‍only disease or OMD of the lung, ablative high conformal radiation or local thermal ablation may be considered if resection is limited by comorbidity, the extent of lung parenchyma resection, or other factors Conformal radiation techniques, including SBRT, are a safe and feasible alternative treatment for oligometastatic colorectal liver and lung metastases (in patients not amenable to surgery) RFA can (also) be used in addition to surgery with the goal of eradicating all visible metastatic sites For patients with liver-‍limited disease failing the available chemotherapeutic options and numerous lesions, radioembolisation should be considered as a treatment option and chemoembolisation may be also considered Use of radioembolisation and chemoembolisation of CLM in earlier treatment lines (as consolidation treatment, etc.) should be limited to clinical trials"
},
{
	"page":"ENAS5304_5.13.0.0",
	"text":"5.13.0.0 Cytoreductive surgery and HIPEC Cytoreductive surgery and HIPEC for patients with peritoneal metastases Complete cytoreductive surgery and HIPEC is close to becoming the accepted standard approach for patients with peritoneal metastases from a colorectal primary and can be considered for patients with limited peritoneal metastases in very experienced centres"
},
{
	"page":"ENAS5304_5.14.1.0",
	"text":"5.14.0.0 Treatment of metastatic disease 5.14.1.0 First-‍line The definition of a treatment aim and strategy are important considerations in multimodal treatment approaches and the choice of a systemic treatment strategy Relevant factors include: tumour-‍ and disease-related characteristics, patient-related factors and treatment-related factors, as shown in the table below   DRIVERS FOR FIRST-‍LINE TREATMENT Tumour characteristics Patient characteristics Treatment characteristics Clinical presentation: Tumour burden Tumour localisation Age Toxicity profile Tumour biology Performance status Flexibility of treatment administration RAS mutation status Organ function Socio-‍economic factors BRAF mutation status Comorbidities, patient attitude, expectation and preference Quality of life"
},
{
	"page":"ENAS5304_5.14.2.0",
	"text":"5.14.2.0 Determination of the therapeutic strategy The therapeutic strategy should be selected following a diagnostic work-‍up including clinical examination, blood counts, determination of liver and renal function, tumour marker measurements (primarily carcinoembryonic antigen [CEA] levels), abdominal and thoracic CT/‍MRI scan and assessment of the patient’s general health General health and performance status (PS) are strong prognostic and predictive factors for chemotherapy and ‘fit’ or ‘unfit’ are used to determine the intensity of treatment choice Three clinically relevant categories are evolving for the treatment of ‘fit’ patients whose metastatic disease is not resectable at presentation Group 1A: Intensive treatment with the goal of cytoreduction and conversion to resectable disease or the use of LAT Group 1B: Intensive treatment for rapid reduction of tumour burden because of impending clinical threat or organ dysfunction, or severe symptoms (although patients will not reach resection or benefit from LAT) Group 2: Intensive treatment is unnecessary and the goal is disease control Knowledge of RAS and BRAF mutational status is required to further refine treatment strategies, as shown in the table below REVISED ESMO GROUPS FOR TREATMENT STRATIFICATION OF PATIENTS ACCORDING TO WHETHER PATIENTS ARE ‘FIT’ OR ‘UNFIT’ PATIENT’S CLASSIFICATION ‘FIT’ PATIENTS ‘UNFIT’ PATIENTS GROUP 1 GROUP 2 Clinical presentation A. Conversion and achievement of NED   B. Impending clinical threat, impending organ dysfunction and severe (disease-related) symptoms   Treatment biomarker driven: RAS wt, RAS mt, BRAF mt patient subgroups Asymptomatic patients No impending clinical threat Resection not an option   Treatment biomarker driven: RAS wt, RAS mt, BRAF mt patient subgroups BSC Treatment goal A. Cytoreduction, followed by R0 resection; NED achieved by LAT   B. Improvement of symptoms and hence avoidance of rapid evolution and prolonged survival Disease control and hence prolonged survival Palliative BSC, best supportive care; LAT, locally ablative treatment; mt, mutant; NED, no evidence of disease; R0, resection with negative margins; wt, wild-type The typical first-‍line treatment options are a cytotoxic doublet (such as FOLFOX, CAPOX or leucovorin/infusional 5-FU/irinotecan [FOLFIRI]) or, in selected patients, a cytotoxic triplet (FOLFOXIRI) Fluoropyrimidine (FP) monotherapy is an option in selected patients with asymptomatic, primarily unresectable metastases that are likely to be eligible for multiple lines of treatment and who are not candidates for combination chemotherapy Biologicals (targeted agents) are indicated in the first-‍line treatment of most patients (unless contraindicated) If the vascular endothelial growth factor (VEGF) antibody bevacizumab is used, it should be combined with Cytotoxic doublets: FOLFOX/CAPOX/FOLFIRI Cytotoxic triplet FOLFOXIRI in selected fit and motivated patients where cytoreduction (tumour shrinkage) is the goal and potentially also in fit patients with tumour BRAF mutations FP monotherapy in patients unable to tolerate aggressive treatment If EGFR antibodies are used, they should be combined with Cytotoxic doublets: FOLFOX/FOLFIRI Capecitabine-‍based and bolus 5-‍FU-‍based doublets should not be combined with EGFR antibodies Recent retrospective analyses of large first (and second) line trials have shown that for patients with RAS wild-type status, combinations with anti-EGFR antibodies have a higher activity in patients with left-sided primary tumours. Conclusions from this finding are: To reinforce the use of EGFR antibody therapy in patients with mCRC and leftsided RAS wild-type tumours  To promote the idea that patients with right-sided RAS wild-type tumours might be better treated with chemotherapy alone or  chemotherapy plus bevacizumab To emphasise that in the absence of data on specific treatment sequences, there is no reason that EGFR-antibody therapy should be avoided in cases of disease progression or treatment intolerance independent of primary tumour location Patients should receive all three available cytotoxic agents and all suitable targeted agents during the course of their treatment, when possible, although the optimal sequence remains to be elucidated Around 70–80% of ‘fit’ patients should receive second-‍line therapy and 50–60% should receive third-‍line therapy"
},
{
	"page":"ENAS5304_5.14.3.0",
	"text":"5.14.3.0 Discont. of Rx. and maint. therapy Discontinuation of treatment and the concept of maintenance therapy After initial induction therapy, an active maintenance treatment is seen as a possible option to shorten duration of induction combination therapy Patients receiving FOLFOX or CAPOX + bevacizumab-‍based therapy as induction therapy, should be considered for maintenance therapy after 6 cycles of CAPOX or 8 cycles of FOLFOX The optimal maintenance treatment is a combination of an FP + bevacizumab Bevacizumab as monotherapy is not recommended Patients receiving FOLFIRI can continue on induction therapy – at a minimum – for as long as tumour shrinkage continues and the treatment is tolerable For patients receiving initial therapy with FOLFOXIRI ± bevacizumab, FP + bevacizumab may be considered as maintenance therapy For patients receiving initial therapy with a single-‍agent FP (+ bevacizumab), induction therapy should be maintained until progression Individualisation and discussion with the patient is essential Initial induction therapy or a second-‍line therapy have to be reintroduced at radiological or first signs of symptomatic progression If a second-‍line therapy is chosen, re-‍introduction of the initial induction treatment should be a part of the entire treatment strategy as long as no relevant residual toxicity is present"
},
{
	"page":"ENAS5304_5.14.4.0",
	"text":"5.14.4.0 Second-‍line Second-‍line therapy is recommended for patients with a good PS and adequate organ function The type of therapy depends on the first-‍line choice and, in patients in whom the initial chemotherapy backbone has failed, the chemotherapy backbone should be changed from that used first line Bevacizumab-‍naïve patients should be considered for treatment with an antiangiogenic (bevacizumab or aflibercept) second line Aflibercept should be restricted to combination with FOLFIRI for patients progressing on an oxaliplatin-containing regimen Patients who received bevacizumab first line should be considered for treatment with Bevacizumab post-‍continuation strategy Aflibercept or ramucirumab (in combination with FOLFIRI) when treated first line with oxaliplatin EGFR antibodies in combination with FOLFIRI/irinotecan for patients with RAS wild-‍type (BRAF wild-‍type) disease The relative benefit of EGFR antibodies is similar in later lines compared with second line Patients who are fast progressors on first-‍line bevacizumab-containing regimens should be considered for treatment with aflibercept or ramucirumab (only in combination with FOLFIRI), and – in the case of patients with RAS wild-‍type disease and no pre-‍treatment with anti-‍EGFR therapy – EGFR antibody therapy, preferably in combination with chemotherapy"
},
{
	"page":"ENAS5304_5.14.5.0",
	"text":"5.14.5.0 Third-‍line In RAS wild-‍type and BRAF wild-‍type patients not previously treated with EGFR antibodies, cetuximab or panitumumab therapy should be considered Cetuximab and panitumumab are equally active as single agents Cetuximab + irinotecan is more active than cetuximab alone in irinotecan-refractory patients There is no evidence to administer the alternative EGFR antibody if a patient is refractory to one of the EGFR antibodies Regorafenib is recommended in patients pre-‍treated with FP, oxaliplatin, irinotecan, bevacizumab and, in RAS wild-‍type patients, with EGFR antibodies Regorafenib is superior to placebo in terms of overall survival (OS) – although there are toxicity concerns Trifluridine/‍tipiracil is recommended for patients pre-‍treated with FP, oxaliplatin, irinotecan, bevacizumab and, in RAS wild-‍type patients, with EGFR antibodies Trifluridine/‍tipiracil is superior to placebo in terms of OS"
},
{
	"page":"ENAS5304_5.14.6.0",
	"text":"Consensus recommendations on the use of cytotoxics and biologicals in the first- and subsequent-line treatment of patients with mCRC 5.14.6.0 Recom. on the use of cytotoxics Allocation of patients to treatment should be done according to the Zurich treatment algorithm, shown in the figure here Allocation to first-‍line treatment Fit patients with resectable metastatic disease Patients can be referred immediately for potentially curative surgery or for perioperative chemotherapy (FOLFOX), depending on the available prognostic information and surgical considerations Fit patients with unresectable metastatic disease Where cytoreduction with conversion and/‍or integration of LAT is the goal, recommended treatment regimens are shown in the table here"
},
{
	"page":"ENAS5304_5.14.8.0",
	"text":"5.14.8.0 Systemic therapy choices SYSTEMIC THERAPY CHOICES ACCORDING TO THE ZURICH TREATMENT ALGORITHM FOR PATIENTS WITH UNRESECTABLE METASTATIC DISEASE (EXCLUDING THOSE WITH OLIGOMETASTATIC DISEASE) Category Fit patients† Treatment goal Cytoreduction (tumour shrinkage) Molecular profile RAS wt RAS mt BRAF mt First Line Preferred choice (s) ChT doublet + EGFR antibody ‡, § ChT doublet + bevacizumab FOLFOXIRI + bevacizumab Second choice (s) FOLFOXIRI +/- bevacizumab FOLFOXIRI + bevacizumab ChT doublet + bevacizumab Third choice (s) ChT doublet + bevacizumab FOLFOXIRI FOLFOXIRI Maintenance Preferred choice FP + bevacizumab‖ FP + bevacizumab FP + bevacizumab Second choice Pause Pause Pause Second-‍line Preferred choice (s) ChT doublet + bevacizumab ChT doublet + bevacizumab ChT doublet + bevacizumab Second choice (s) ChT doublet + EGFR antibody ‡, ¶ or FOLFIRI + aflibercept/ ramucirumab FOLFIRI + aflibercept/ ramucirumab FOLFIRI + aflibercept/ ramucirumab Third-‍line Preferred choice (s) ChT doublet + EGFR antibody ‡, ¶ or Irinotecan + cetuximabe¶ Regorafenib or trifluridine/‍tipiracil Regorafenib or trifluridine/‍tipiracil Second choice EGFR antibody monotherapy¶     Third choice (s) Regorafenib or trifluridine/‍tipiracil     Treatment goal Disease control (control of progression) Molecular profile RAS wt RAS mt BRAF mt First Line Preferred choice (s) ChT doublet + bevacizumab or ChT doublet + EGFR antibody ‡ ChT doublet + bevacizumab FOLFOXIRI +/- bevacizumab Second choice (s) FP + bevacizumab   ChT doublet + bevacizumab Third choice (s)       Maintenance Preferred choice FP + bevacizumab‖ FP + bevacizumab FP + bevacizumab Second choice Pause Pause Pause Second-‍line Preferred choice (s) ChT doublet + bevacizumab or ChT doublet + EGFR antibody ChT doublet + bevacizumab ChT doublet + bevacizumab Second choice (s) FOLFIRI + aflibercept/ ramucirumab FOLFIRI + aflibercept/ ramucirumab FOLFIRI + aflibercept/ ramucirumab Third-‍line Preferred choice (s) ChT doublet + EGFR antibody ‡ or Irinotecan + cetuximab Regorafenib or trifluridine/‍tipiracil Regorafenib or trifluridine/‍tipiracil Second choice EGFR antibody monotherapy¶     Third choice (s) Regorafenib or trifluridine/‍tipiracil     Category Unfit† (May be unfit) Treatment goal Palliation Molecular profile Any First Line Preferred choice (s) FP + bevacizumab Second choice (s) Reduced-‍dose ChT doublet Third choice (s) If RAS wt may consider EGFR antibody therapy Maintenance Preferred choice FP + bevacizumab Second choice FP Second-‍line Preferred choice (s)   Second choice (s)   Third-‍line Preferred choice (s)   Second choice   Third choice (s)   Category Unfit† (Unfit) Treatment goal Palliation Molecular profile Any First Line Preferred choice (s) BSC Second choice (s) - Third choice (s) - Maintenance Preferred choice - Second choice - Second-‍line Preferred choice (s) - Second choice (s) - Third-‍line Preferred choice (s) - Second choice - Third choice (s) - BSC, best supportive care; ChT, chemotherapy; EGFR, epidermal growth factor receptor; FOLFIRI, leucovorin/infusional 5-fluorouracil/irinotecan; FOLFOXIRI, leucovorin/infusional 5-fluorouracil/oxaliplatin/irinotecan; FP, fluoropyrimidine; mt, mutant; wt, wild-type *See also figure on the previous page †Patients assessed as fit or unfit according to medical condition not due to malignant disease ‡EGFR antibodies: cetuximab and panitumumab §In patients in need of a rapid reduction of tumour burden because of impending clinical threat, impending organ dysfunction and severe disease-related symptoms a similar strategy can be proposed, although the consensus on the preferred treatment of choice was less strong. For those patients who have RAS wild-‍type disease, a cytotoxic doublet + an EGFR antibody is a preferred option, although a cytotoxic doublet + bevacizumab is an equally valid alternative. A cytotoxic triplet ± bevacizumab may be an alternative for selected, very fit and motivated patients ‖In patients where a bevacizumab-containing regimen was started. In patients where a cetuximab-containing combination was started: pause or less intensive regimen ¶If not yet pretreated with an EGFR antibody"
},
{
	"page":"ENAS5304_5.14.9.0",
	"text":"5.14.9.0 Further recom. for treatment selection Further recommendations for treatment selection in this situation A cytotoxic doublet + an EGFR antibody is recommended for RAS wild-‍type disease A cytotoxic doublet + bevacizumab or cytotoxic triplet + bevacizumab are the preferred options for RAS mutant disease Disease status should be re-‍evaluated every 2 months to ensure that patients with resectable disease are not overtreated Where there is evidence of tumour shrinkage after the first 2 months, patients should be recommended for either potentially curative surgery or the most suitable LAT strategy, with a view to eliminating all evidence of disease (i.e. R0 resection, NED) Where no response is evident at the first evaluation, the cytotoxic doublet should be changed Where there is evidence of cytoreduction but the patient is not suitable for surgery, combination chemotherapy + the appropriate biological (dependent on RAS and BRAF mutation status) should be continued until the start of the post-‍induction treatment phase (active maintenance treatment or withdrawal of treatment) Where there is evidence of disease progression, patients should continue to second-‍line therapy, as shown in the figure here Toxicity may require a change to an alternative regimen"
},
{
	"page":"ENAS5304_5.14.10.2",
	"text":"5.14.10.2 Fit patients with symptomatic disease Where cytoreduction is needed because of aggressive biology and/‍or risk of developing/‍exacerbating severe symptoms A cytotoxic doublet + an EGFR antibody is preferred for RAS wild-‍type disease, although a cytotoxic doublet + bevacizumab is equally valid A cytotoxic triplet ± bevacizumab may be an alternative for selected, very fit and motivated patients Where disease control is the goal A cytotoxic doublet in combination with either bevacizumab or (in patients with RAS wild-‍type tumours) with an EGFR antibody is recommended A cytotoxic doublet + bevacizumab is the preferred option for RAS mutant disease A cytotoxic triplet ± bevacizumab may be an alternative for selected, very fit and motivated patients General procedures Disease status should be re-‍evaluated every 2–3 months In patients with a good response, or at least disease control, active maintenance therapy should be considered, preferably with an FP + bevacizumab if a cytotoxic doublet + bevacizumab was the initial approach Where there is evidence of disease progression, patients should continue to second-‍line therapy, as shown in the figure here Toxicity may also require a change to second-‍line therapy"
},
{
	"page":"ENAS5304_5.14.10.3",
	"text":"5.14.10.3 Unfit patients Patients unfit for any treatment should receive best supportive care (BSC) Potential treatment options for unfit patients suitable for treatment may be capecitabine + bevacizumab or a reduced-‍dose cytotoxic doublet Anti-‍EGFR therapy can be considered as a last line of treatment for RAS wild-‍type disease"
},
{
	"page":"ENAS5304_5.14.10.4",
	"text":"5.14.10.4 Elderly patients Fit older patients should be treated with systemic combination therapy + targeted agents as they receive the same benefit as younger patients Older patients unfit for standard combination therapy may benefit from less intensive therapies, including capecitabine + bevacizumab or reduced-‍dose FP + oxaliplatin or irinotecan"
},
{
	"page":"ENAS5304_6.0.0.0",
	"text":"6.0.0.0 PERSONALISED MEDICINE It is important to select patients for anti-‍EGFR antibodies on the basis of the molecular characteristics of the tumour A BRAF mutation is a strong negative prognostic biomarker Patients may benefit from more intensive regimens There are no validated biomarkers available for either angiogenesis inhibitors or regorafenib"
},
{
	"page":"ENAS5304_7.0.0.0",
	"text":"7.0.0.0 RESPONSE EVALUATION AND FOLLOW-‍UP After 2–3 months of palliative chemotherapy, the following assessments are recommended History, including evaluation of general condition, side effects of chemotherapy and impact on quality of life Physical examination CEA, if initially elevated CT (or MRI) scan of involved regions Patients should be re-‍assessed every 2–3 months if chemotherapy is continued A follow-‍up with CEA and CT scan at intervals of 3–6 months during the first 3 years is recommended in patients who underwent a complete resection of metastatic disease"
},
{
	"page":"ENAS5304_8.1.0.0",
	"text":"8.0.0.0 Summary of recommendations 8.1.0.0 DIAGNOSIS Clinical or biochemical suspicion of mCRC should always be confirmed by radiological imaging and histological confirmation The first choice is an abdominal/‍pelvic and thoracic CT scan followed, in cases of doubt or if further information is required by a second method, such as US (including CEUS), MRI or PET-‍CT scan, depending on the localisation of the metastases A stepwise imaging approach is recommended in relation to therapeutic possibilities, rather than the use of all imaging modalities in all patients"
},
{
	"page":"ENAS5304_8.2.0.0",
	"text":"8.2.0.0 MOLECULAR PATHOLOGY AND BIOMARKERS Ideally, 10 diagnostic tumour/‍biopsy/‍endoscopy samples should be collected Additional frozen material should be collected to facilitate any future ‘new’ tests"
},
{
	"page":"ENAS5304_8.3.0.0",
	"text":"8.3.0.0 Tissue handling The time between tissue sampling and fixation should be minimised (to a few minutes) to prevent degradation of proteins and nucleic acids Biomarker analysis should ideally be carried out immediately after the sections have been cut and within 4–6 weeks"
},
{
	"page":"ENAS5304_8.4.0.0",
	"text":"8.4.0.0 Tissue selection for biomarker testing Archival primary tumour tissue can be used for testing, as well as biopsies of the primary or metastatic lesions For RAS mutation testing, tissue from a primary tumour or liver metastasis is recommended Tissue from other metastatic sites, such as lymph node or lung, should be used only when primary tumour or liver metastases samples are not available"
},
{
	"page":"ENAS5304_8.5.1.0",
	"text":"8.5.0.0 RAS, BRAF and MSI 8.5.1.0 RAS Expanded RAS analysis should be conducted on all patients eligible/‍being considered for treatment with anti-‍EGFR antibodies (cetuximab and panitumumab) This should include at least KRAS exons 2, 3 and 4 (codons 12, 13, 59, 61, 117 and 146) and NRAS exons 2, 3 and 4 (codons 12, 13, 59, 61 and 117) The exact cut-‍off for clinically relevant RAS mutant allele frequencies has not been determined Turnaround time for (expanded) RAS testing should be ≤ 7 working days from the time of receipt of the specimen by the testing laboratory to the time of issuing of the final report for most specimens Validation, and/‍or verification, of RAS testing assays is required and laboratories should be appropriately accredited"
},
{
	"page":"ENAS5304_8.5.2.0",
	"text":"8.5.2.0 BRAF BRAF mutation status should be assessed alongside the assessment of RAS mutation status, ideally at diagnosis, for prognostic assessment and/‍or potential determination of treatment intensity and for selection for clinical trials"
},
{
	"page":"ENAS5304_8.5.3.0",
	"text":"8.5.3.0 Microsatellite instability MSI testing can assist in the setting of genetic counselling MSI seems to be strongly predictive for the clinical benefit of immune checkpoint inhibitors"
},
{
	"page":"ENAS5304_8.5.4.0",
	"text":"8.5.4.0 ChT sensitivity/‍ toxicity biomarkers DPD testing before 5-FU administration is not generally recommended UGT1A1 phenotyping should be performed in patients with a suspicion of UGT1A1 deficiency and in patients where an irinotecan dose of > 180 mg/m2 per administration is planned ERCC1 expression, TS activity and TSER genotyping are not recommended for use in clinical practice"
},
{
	"page":"ENAS5304_8.6.1.0",
	"text":"8.6.0.0 Treatment 8.6.1.0 Overview The optimal treatment of mCRC should involve an expert MDT, including a colorectal surgeon, a specialist hepatobiliary and/‍or lung surgeon, a pathologist, a diagnostic radiologist and radiation and medical oncologists as standard"
},
{
	"page":"ENAS5304_8.6.2.1",
	"text":"8.6.2.0 Mgmt. of patients with OMD, LAT, surgery 8.6.2.1 Oligometastatic disease Treatment should be based on the possibility of achieving complete ablation of all tumour masses using surgical R0 resection and/‍or LAT For OMD confined to a single organ (commonly the liver), or a few organs, surgery is the standard treatment and is potentially curative For more extensive OMD, involving more sites or lesions, systemic treatment is the standard of care and should be considered as the initial part of every treatment strategy The best local treatment should be selected from a toolbox of procedures, according to disease localisation, treatment goal, treatment-related morbidity and patient-related factors, such as comorbidities and age Liver-‍directed therapy is the best-‍established approach, but other options include SBRT and RFA, peritonectomy with/‍without HIPEC and nodal dissection Patients with lung metastases have better outcomes and a ‘watch and wait’ strategy (or sequential approach) may be appropriate"
},
{
	"page":"ENAS5304_8.6.2.2",
	"text":"8.6.2.2 Liver metastases and surgical resection The treatment strategy for CLM should be directed towards complete resection, whenever possible, based on oncological and technical criteria"
},
{
	"page":"ENAS5304_8.6.2.3",
	"text":"Imaging in the identification of resectable/unresectable disease Imaging should comprise firstly an abdominal/‍pelvic and thoracic CT scan and, in the case of doubt, a second method – such as US (CEUS), MRI or PET/‍CT scan depending on the localisation of the metastases A stepwise imaging approach is the recommended policy, in relation to the therapeutic possibilities, rather than the use of all imaging modalities in all patients For metachronous metastases, histopathological or cytological confirmation of metastases should be obtained if the clinical or radiological presentation is either atypical or very late (e.g. later than 3 years) after the initial diagnosis of the primary tumour Resectable metastases do not need histological or cytological confirmation before resection"
},
{
	"page":"ENAS5304_8.6.2.4",
	"text":"Liver metastases that are technically resectable up front In patients with clearly resectable disease and favourable prognostic criteria, perioperative treatment may not be necessary and upfront R0 resection is justified In technically resectable disease where the prognosis is unclear or probably unfavourable, perioperative FOLFOX or CAPOX (3 months prior to and post-‍surgery) should be administered Targeted agents should not be used in this setting Adjuvant chemotherapy is not recommended for patients with favourable oncological and technical (surgical) criteria who have not received perioperative chemotherapy, but may be beneficial for patients with unfavourable criteria In patients who have not received any previous chemotherapy, adjuvant FOLFOX or CAPOX is recommended (unless patients were previously recently exposed to oxaliplatin-‍based adjuvant chemotherapy) Decision-‍making should include the patient’s characteristics and preferences"
},
{
	"page":"ENAS5304_8.6.2.5",
	"text":"Unresectable colorectal liver metastases with ‘conversion’ as a strategic treatment goal Any patient with limited liver and/‍or lung metastases should be considered a candidate for potential secondary resection Response to systemic treatment is a strong prognostic indicator with conversion therapy Resectability should be assessed after 2 and then 4 months of optimal treatment Up to 75% of patients will relapse (mainly in the liver) and ablative techniques, such as RFA or SBRT, may be used as an adjunct to surgery to achieve NED There is currently no standard for the treatment of synchronous CLM but the recommendation is for more aggressive treatment and preoperative chemotherapy"
},
{
	"page":"ENAS5304_8.6.3.0",
	"text":"8.6.3.0 Conversion treatment Regimens leading to high RRs and/‍or large tumour reduction are recommended for potentially resectable disease with conversion as the goal There is uncertainty surrounding the best combination In patients with RAS wild-‍type disease, a cytotoxic doublet + an anti-‍EGFR antibody seems to have the best benefit risk/‍ratio, although the combination of FOLFOXIRI + bevacizumab may also be considered and, to a lesser extent, a cytotoxic doublet plus bevacizumab In patients with RAS mutant disease: a cytotoxic doublet + bevacizumab or FOLFOXIRI + bevacizumab Patients must be re-‍evaluated regularly to prevent the overtreatment of resectable disease Total therapy duration should not exceed 6 months"
},
{
	"page":"ENAS5304_8.6.4.0",
	"text":"Metastases at unfavourable/uncommon sites and role of ablative treatment with or without surgery Patients with a limited number of lesions and involved sites should be regarded as having OMD and should be treated according to the standard treatment algorithm RFA, microwave ablation, cryoablation, SBRT and, to a lesser extent, embolisation techniques are all feasible Selection of ablative treatments from the toolbox differ according to the size and localisation of metastases, the rates of control achieved, the invasiveness of the technique, prognostic considerations, patient factors and preferences, local expertise and life expectancy This strategic treatment approach should be evaluated and pursued further in suitable patients"
},
{
	"page":"ENAS5304_8.6.5.0",
	"text":"8.6.5.0 Toolbox of LATs Current techniques within the LAT toolbox comprise local thermal ablation, conformal radiation techniques, chemoembolisation or radioembolisation with yttrium-‍labelled microspheres In patients with unresectable liver metastases only, or OMD, LAT, such as thermal ablation or high conformal radiation techniques (e.g. SBRT, HDR-‍brachytherapy), can be considered The decision should be taken by a MDT, based on tumour and disease characteristics, local experience of the treating MDT and patient preference In patients with lung-‍only disease or OMD of the lung, ablative high conformal radiation or thermal ablation may be considered if resection is limited by comorbidity, the extent of lung parenchyma resection, or other factors Conformal radiation techniques, including SBRT, are a safe and feasible alternative treatment for oligometastatic colorectal liver and lung metastases (in patients not amenable to surgery) RFA can (also) be used in addition to surgery with the goal of eradicating all visible metastatic sites For patients with liver-‍limited disease failing the available chemotherapeutic options and numerous lesions, radioembolisation should be considered as a treatment option and chemoembolisation may be also considered"
},
{
	"page":"ENAS5304_8.6.6.0",
	"text":"Cytoreductive surgery and HIPEC for patients with peritoneal metastases Complete cytoreductive surgery and HIPEC can be considered for patients with limited peritoneal metastases in very experienced centres"
},
{
	"page":"ENAS5304_8.6.7.0",
	"text":"8.6.7.0 Treatment of metastatic disease The definition of a treatment aim and strategy are important considerations in multimodal treatment approaches and the choice of a systemic treatment strategy Relevant factors include: tumour-‍ and disease-related characteristics, patient-related factors and treatment-related factors"
},
{
	"page":"ENAS5304_8.6.8.0",
	"text":"8.6.8.0 Determination of the therapeutic strategy The therapeutic strategy should be selected following a clinical examination, blood counts, determination of liver and renal function, tumour marker measurements (primarily CEA levels), abdominal and thoracic CT/‍MRI scan and assessment of general health General health and PS are strong prognostic and predictive factors for chemotherapy and ‘fit’ or ‘unfit’ are used to determine the intensity of treatment choice Knowledge of RAS and BRAF mutational status is required to further refine treatment strategies The typical first-‍line treatment options are a cytotoxic doublet (such as FOLFOX, CAPOX or FOLFIRI) or, in selected patients, triplet (FOLFOXIRI) FP monotherapy is an option in selected patients with asymptomatic, primarily unresectable metastases that are likely to be eligible for multiple lines of treatment and who are not candidates for combination chemotherapy Biologicals (targeted agents) are indicated in the first-‍line treatment of most patients (unless contraindicated) If the VEGF antibody bevacizumab is used, it should be combined with Cytotoxic doublets: FOLFOX/CAPOX/FOLFIRI Cytotoxic triplet FOLFOXIRI in selected fit and motivated patients where cytoreduction (tumour shrinkage) is the goal – and potentially also in fit patients with tumour BRAF mutations FP monotherapy in patients unable to tolerate aggressive treatment If EGFR antibodies are used, they should be combined with Cytotoxic doublets: FOLFOX/FOLFIRI Capecitabine-‍based and bolus 5-‍FU-‍based doublets should not be combined with EGFR antibodies Recent retrospective analyses of large first (and second) line trials have shown that for patients with RAS wild-type status, combinations with anti-EGFR antibodies have a higher activity in patients with left-sided primary tumours. Conclusions from this finding are: To reinforce the use of EGFR antibody therapy in patients with mCRC and leftsided RAS wild-type tumours To promote the idea that patients with right-sided RAS wild-type tumours might be better treated with chemotherapy alone or chemotherapy plus bevacizumab To emphasise that in the absence of data on specific treatment sequences, there is no reason that EGFR-antibody therapy should be avoided in cases of disease progression or treatment intolerance independent of primary tumour location Patients should receive all three available cytotoxic agents and all targeted agents during the course of their treatment, when possible, although the optimal sequence remains to be elucidated"
},
{
	"page":"ENAS5304_8.6.9.0",
	"text":"Discontinuation of treatment and the concept of maintenance therapy Patients receiving FOLFOX or CAPOX + bevacizumab-‍based therapy as induction therapy, should be considered for maintenance therapy after 6 cycles of CAPOX and 8 cycles of FOLFOX The optimal maintenance treatment is a combination of an FP + bevacizumab Bevacizumab as monotherapy is not recommended Patients receiving FOLFIRI can continue on induction therapy – at a minimum – for as long as tumour shrinkage continues and the treatment is tolerable For patients receiving initial therapy with FOLFOXIRI ± bevacizumab, FP + bevacizumab may be considered as maintenance therapy For patients receiving initial therapy with a single-‍agent FP (+ bevacizumab), induction therapy should be maintained until progression Individualisation and discussion with the patient is essential Initial induction therapy or a second-‍line therapy have to be reintroduced at radiological or first signs of symptomatic progression If a second-‍line therapy is chosen, re-‍introduction of the initial induction treatment should be a part of the entire treatment strategy as long as no relevant residual toxicity is present"
},
{
	"page":"ENAS5304_8.6.10.0",
	"text":"8.6.10.0 Second-‍line Second-‍line therapy is recommended for patients with a good PS and adequate organ function The type of therapy depends on the first-‍line choice and, in patients in whom the initial chemotherapy backbone has failed, the chemotherapy backbone should be changed from that used first line Patients who are bevacizumab naïve should be considered for treatment with an antiangiogenic (bevacizumab or aflibercept) second line Aflibercept should be restricted to combination with FOLFIRI for patients progressing on an oxaliplatin-containing regimen Patients who received bevacizumab first line should be considered for treatment with Bevacizumab post-‍continuation strategy Aflibercept or ramucirumab (in combination with FOLFIRI) when treated first line with oxaliplatin EGFR antibodies in combination with FOLFIRI/irinotecan for patients with RAS wild-‍type (BRAF wild-‍type) disease Patients who are fast progressors on first-‍line bevacizumab-containing regimens should be considered for treatment with aflibercept or ramucirumab (only in combination with FOLFIRI), and – in the case of patients with RAS wild-‍type disease and no pre-‍treatment with anti-‍EGFR therapy – EGFR antibody therapy, preferably in combination with chemotherapy"
},
{
	"page":"ENAS5304_8.6.11.0",
	"text":"8.6.11.0 Third-‍line In RAS wild-‍type and BRAF wild-‍type patients not previously treated with EGFR antibodies, cetuximab or panitumumab therapy should be considered Regorafenib is recommended in patients pre-‍treated with FP, oxaliplatin, irinotecan, bevacizumab and, in RAS wild-‍type patients, with EGFR antibodies Trifluridine/‍tipiracil is recommended for patients pre-‍treated with FP, oxaliplatin, irinotecan, bevacizumab and, in RAS wild-‍type patients, with EGFR antibodies"
},
{
	"page":"ENAS5304_8.6.12.1",
	"text":"Consensus recommendations on the use of cytotoxics and biologicals in the first- and subsequent-line treatment of patients with mCRC 8.6.12.0 Recom. on the use of cytotoxics 8.6.12.1 Allocation to first-‍line treatment Allocation of patients to treatment should be done according to the Zurich treatment algorithm Allocation to first-‍line treatment Fit patients with resectable metastatic disease Patients can be referred immediately for potentially curative surgery or for perioperative FOLFOX, depending on the available prognostic information and surgical considerations Fit patients with unresectable metastatic disease Where cytoreduction with conversion and/‍or integration of LAT is the goal, the recommendations are A cytotoxic doublet + an EGFR antibody for RAS wild-‍type disease A cytotoxic doublet + bevacizumab or cytotoxic triplet + bevacizumab for RAS mutant disease Disease status should be re-‍evaluated every 2 months to ensure that patients with resectable disease are not overtreated Where there is evidence of tumour shrinkage after the first 2 months, patients should be recommended for either potentially curative surgery or the most suitable LAT strategy, with a view to eliminating all evidence of disease (i.e. R0 resection, NED) Where no response is evident at the first evaluation, the cytotoxic doublet should be changed Where there is evidence of cytoreduction but the patient is not suitable for surgery, combination chemotherapy + the appropriate biological (dependent on RAS and BRAF mutation status) should be continued until the start of the post-‍induction treatment phase (active maintenance treatment or withdrawal of treatment) Where there is evidence of disease progression, patients should continue to second-‍line therapy Fit patients with symptomatic disease Where cytoreduction is needed because of aggressive biology and/‍or risk of developing/‍exacerbating severe symptoms A cytotoxic doublet + an EGFR antibody is preferred for RAS wild-‍type disease, although a cytotoxic doublet + bevacizumab is equally valid A cytotoxic triplet ± bevacizumab may be an alternative for selected, very fit and motivated patients Where disease control is the goal A cytotoxic doublet in combination with either bevacizumab or (in patients with RAS wild-‍type tumours) with an EGFR antibody is recommended A cytotoxic doublet + bevacizumab is the preferred option for RAS mutant disease A cytotoxic triplet ± bevacizumab may be an alternative for selected, very fit and motivated patients General procedures In patients with a good response, or at least disease control, active maintenance therapy should be considered, preferably with an FP + bevacizumab if a cytotoxic doublet + bevacizumab was the initial approach Where there is evidence of disease progression, patients should continue to second-‍line therapy"
},
{
	"page":"ENAS5304_8.6.12.2",
	"text":"8.6.12.2 Unfit patients Patients unfit for any treatment should receive BSC Potential treatment options for unfit patients may be capecitabine + bevacizumab or a reduced-‍dose cytotoxic doublet Anti-‍EGFR therapy can be considered as a last line of treatment for RAS wild-‍type disease"
},
{
	"page":"ENAS5304_8.6.12.3",
	"text":"8.6.12.3 Elderly patients Fit older patients should be treated with systemic combination therapy + targeted agents as they receive the same benefit as younger patients Older patients unfit for standard combination therapy may benefit from less intensive therapies, including capecitabine + bevacizumab or reduced-‍dose FP + oxaliplatin or irinotecan"
},
{
	"page":"ENAS5304_8.7.0.0",
	"text":"8.7.0.0 PERSONALISED MEDICINE It is important to select patients for anti-‍EGFR antibodies on the basis of the molecular characteristics of the tumour RAS testing is standard A BRAF mutation is a strong negative prognostic biomarker Patients may benefit from more intensive regimens"
},
{
	"page":"ENAS5304_8.8.0.0",
	"text":"8.8.0.0 RESPONSE EVALUATION AND FOLLOW-‍UP Patients should be re-‍assessed every 2–3 months if chemotherapy is continued A follow-‍up with CEA and CT scan at intervals of 3–6 months during the first 3 years is recommended in patients who underwent a complete resection of metastatic disease"
},
{
	"page":"ENAS5304_9.0.0.0",
	"text":"Glossary 5-FU 5-‍fluorouracil ACD anal cancer death ADC Apparent Diffusion Coefficient AFAP attenuated familial adenomatous polyposis AJCC American Joint Committee for Cancer APE abdomino-‍‍perineal excision APPA anterior posterior/‍‍posterior anterior BSC best supportive care CA19-9 carbohydrate antigen 19-9 CAPOX capecitabine/‍oxaliplatin cCR clinical complete remission CEA carcinoembryonic antigen CEUS contrast-‍‍enhanced ultrasound cfDNA cell-‍free DNA ChT chemotherapy CIN cervical intra-epithelial neoplasia CLM colorectal liver metastases cN clinical node stage CPGs Clinical Practice Guidelines CRC colorectal cancer CRM circumferential resection margin CRT chemoradiotherapy cT clinical tumour stage CT computed tomography CTC circulating tumour cell ctDNA circulating tumour DNA DCC deleted in colon cancer DFS disease-‍‍free survival dMMR mismatch repair deficient DNA deoxyribonucleic acid DPD dihydropyrimidine dehydrogenase DRE digital rectal examination EAUS endo-‍anal ultrasound EGFR epidermal growth factor receptor EMVI extramural vascular invasion ENE extranodal extension ERCC1 excision repair cross-‍‍complementation group1 ERUS endoscopic rectal ultrasound ESMO European Society for Medical Oncology ESSO European Society of Surgical Oncology ESTRO European Society for Radiotherapy and Oncology EU European Union EUA examination under anaesthesia EURECCA European Registry of Cancer Care FA folinic acid FAP familial adenomatous polyposis FDG fluorodeoxyglucose FDG-‍PET fluorodeoxyglucose positron emission tomography FIT faecal immunochemical test FLOX 5-‍fluorouracil/leucovorin (folinic acid)/‍oxaliplatin FOBT faecal occult blood test FOLFIRI leucovorin/infusional 5-FU/irinotecan FOLFOX leucovorin/infusional 5-FU/oxaliplatin FOLFOXIRI leucovorin/infusional 5-FU/oxaliplatin/irinotecan FP fluoropyrimidine FS flexible sigmoidoscopy G Grade gFOBT guaiac faecal occult blood test GI gastrointestinal H&E hematoxilin and eosin HAART highly active antiretroviral therapy HDR high dose-‍rate HER2 human epidermal growth factor receptor 2 HIPEC hyperthermic intraperitoneal chemotherapy HIV human immunodeficiency virus HPV human papillomavirus IHC immunohistochemistry IMRT intensity-‍modulated radiotherapy IPAA ileal pouch-‍‍anal anastomosis IRA ileorectal anastomosis IV intravenous L lymphatic invasion LARC locally advanced rectal cancer LAT local ablative treatment LND laternal node dissection LPLN lateral pelvic lymph node LRF locoregional failure rate LV leucovorin MAC modified Astler-‍‍Coller classification MAP MUTYH-‍‍associated polyposis mCRC metastatic colorectal cancer MDT multidisciplinary team MMC mitomycin C MMR mismatch repair MRF mesorectal fascia MRI magnetic resonance imaging mriTRG MRI tumour regression grading MSI microsatellite instability MSI-H microsatellite instability high mt mutant NACT neoadjuvant chemotherapy NCCN National Comprehensive Cancer Network NED no evidence of disease OMD oligometastatic disease OS overall survival pCR pathological complete response PET positron emission tomography PET-CT positron emission tomography-computed tomography PNI perineural invasion PS performance status PTEN phosphatase and tensin homologue QoL quality of life R0 resection with negative margins R1 resection with microscopic residual disease RCT randomised controlled trial RFA radiofrequency ablation RR response rate RT radiotherapy RTOG Radiation Therapy Oncology Group SBRT stereotactic body radiotherapy SCCA squamous cell carcinoma of the anus SCCAg squamous cell carcinoma antigen SCPRT short-course preoperative radiotherapy SIRT selective internal radiotherapy sm submucosa TACE transarterial chemoembolisation TaTME transanal total mesorectal excision TEM transanal endoscopic microsurgery TGF-α transforming growth factor-‍‍α TGFBR2 transforming growth factor-‍‍beta receptor II Tis carcinoma in situ TME total mesorectal excision TNM tumour node metastasis TRG tumour regression grade TS thymidylate synthase TSER thymidylate synthase enhancer region UGT1A1 uridine diphosphate glucuronosyltransferase 1A1 UICC Union for International Cancer Control US ultrasound V vascular invasion VEGF vascular endothelial growth factor VIN vulval intra-‍‍epithelial neoplasia wt wild-‍type XELOX capecitabine/‍oxaliplatin yp neoadjuvant pathological staging"
}
]